Related Experiment Videos
Bronchodilating effect of intravenous magnesium sulfate in acute severe bronchial asthma
M Noppen1, L Vanmaele, N Impens
1Department of Pulmonology, Academic Hospital, Vrije University Brussel, Belgium.
Abstract:
We investigated the bronchodilating effect of intravenous MgSO4 in acute severe bronchial asthma. Infusion of MgSO4 caused a significant improvement in FEV1 (0.94 +/- 0.39L to 1.3 +/- 0.44 L) and an improvement in clinical signs and symptoms in ten out of 12 administrations. The bronchodilating effect of MgSO4, however, was significantly less than that of subsequent albuterol inhalation (FEV1 improvement from 1.13 +/- 0.41 L to 1.72 +/- 0.49 L). These findings confirm that intravenous MgSO4 may be used as an adjunct to classic beta 2-agonist therapy in cases of severe acute asthma; its exact place in the treatment of asthma remains to be determined in large-scale studies.
Insights
Intravenous magnesium sulfate (MgSO4) offers a bronchodilating effect in severe asthma, improving lung function and symptoms. However, its effect is less potent than albuterol, suggesting it as a potential adjunctive therapy for acute severe asthma.
Area of Science:
- Pulmonology
- Emergency Medicine
- Pharmacology
Background:
- Acute severe bronchial asthma requires effective bronchodilator therapy.
- The role of magnesium sulfate in asthma management is an area of ongoing research.
Purpose of the Study:
- To investigate the bronchodilating efficacy of intravenous magnesium sulfate (MgSO4) in patients with acute severe bronchial asthma.
- To compare the effects of MgSO4 with standard beta 2-agonist therapy.
Main Methods:
- A study involving intravenous administration of MgSO4 to patients with acute severe bronchial asthma.
- Measurement of forced expiratory volume in 1 second (FEV1) before and after MgSO4 infusion.
- Comparison of FEV1 changes with those observed after subsequent albuterol inhalation.
Main Results:
- Intravenous MgSO4 significantly improved FEV1 from 0.94 L to 1.3 L.
- Clinical signs and symptoms improved in 10 out of 12 administrations of MgSO4.
- The bronchodilating effect of MgSO4 was significantly less pronounced than that of albuterol inhalation.
Conclusions:
- Intravenous MgSO4 demonstrates a bronchodilating effect in acute severe asthma.
- MgSO4 may serve as an adjunct therapy to beta 2-agonists in severe asthma cases.
- Further large-scale studies are needed to define the optimal role of MgSO4 in asthma treatment.